Champions Oncology (CSBR) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Champions Oncology (CSBR) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 23.0% versus a loss of 57.5%. Over five years, CSBR leads with a -50.6% price change compared with -75.5% for ONCY. Oncolytics Biotech is the larger company by market cap ($71.4 million vs $69.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | ONCY |
|---|---|---|
| Share price | $4.98 | $0.5444 |
| Market cap | $69.31M | $71.38M |
| 1-day change | +2.05% | -8.63% |
| YTD return | -27.93% | -37.43% |
| 1-year return | -23.03% | -57.47% |
| 5-year return | -50.60% | -75.48% |
| Forward P/E | 49.80 | — |
| EPS (TTM) | $-0.07 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.31 | $1.32 |
| 52-week low | $4.59 | $0.54 |
| Distance from 52-week high | -40.07% | -58.76% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +662.31% |
| Average volume | 11.33K | 1.08M |
| Shares outstanding | 13.92M | 131.12M |
| Employees | 214 | 29 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed ONCY by 34.4 percentage points over the past year.
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Healthcare · Biotechnology · 214 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Healthcare · Biotechnology · 29 employees
CSBR vs ONCY FAQ
Which is bigger, Champions Oncology or Oncolytics Biotech?
Oncolytics Biotech (ONCY) is larger, with a market capitalization of $71.38M compared with $69.31M for Champions Oncology (CSBR).
Which stock has performed better over the past year, CSBR or ONCY?
CSBR returned -23.03% over the past 12 months, compared with -57.47% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.